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Objectives. Gastric adenocarcinomas localized to the cardia are increasing. Enterochromaﬃn-like (ECL) cells play a role in gastric
carcinogenesis in hypergastrinemia, and the use of proton pump inhibitors (PPI) leading to hypergastrinemia has increased
considerably during the last decades. We have examined cardia cancers for neuroendocrine and ECL cell diﬀerentiation. Methods.
Thirty-twocardiacancers wereexaminedbyimmunohistochemicallabellingofchromograninA(CgA),synaptophysin,serotonin,
andhistidinedecarboxylase(HDC).InformationaboutPPIusewascollectedfromthepatientrecords.Results.In15of32tumours,
there were positive signs for one or several neuroendocrine markers. Five cases were CgA and serotonin positive; three of these
carcinomas were also positive for HDC. Three patients were long-term users of PPI, and two of these were immunoreactive
for neuroendocrine markers. Conclusions. A high proportion of cardia cancers expressed neuroendocrine markers, but only few
patients with cardia cancers were using PPI.
1.Introduction
Gastric adenocarcinoma has shown a marked decline in the
last decades [1]. Nevertheless, there seems to be an increase
in carcinomas localized to the cardia [2–5], especially in
younger women and older men [6]. However, other studies
have failed to demonstrate such an increase [7–9].
Little is known about the mechanisms for the develop-
ment of cardia cancers. Adenocarcinomas of the esophagus
and cardia share some epidemiological features, including
incidence trends and sex distribution [9], but could have
diﬀerent risk factors. Oesophageal carcinoma is associated
with reﬂux disease, obesity, hiatal hernia, and smoking, but
these factors may have weak or no association with cardia
cancer [10–13].
H. pylori infection is associated with cancers distal to
cardia,butincardiacancersthereseemstobeanegativeasso-
ciation [14]. Hypergastrinemia is associated with noncardia
cancers, but not with cardia cancers in general. However, in
H. Pylori-positive persons, there may be an association [14].
Neuroendocrine cells comprise about 1% of the volume
of the gastric oxyntic mucosa [15], but little is known
about the presence of neuroendocrine cells in the cardia.
One study indicates that neuroendocrine cells in the normal
cardia stain positive for serotonin only [16], occurring
in an inﬂamed cardiac mucosa independent of intestinal
metaplasia, a well-known risk factor for cardia cancer [17].
However, the presence of enterochromaﬃn-like (ECL) cells
was not examined.
We have repeatedly shown that the ECL cell plays an
important role in gastric carcinogenesis [18–21]. The growth
of the ECL cell is mainly regulated by gastrin, which
in turn reﬂects gastric acidity. Since the use of eﬃcient
inhibitors of gastric acid secretion leading to hypoacidity
and hypergastrinemia has increased dramatically during the
last decades, we wanted to retrospectively examine gastric
cardiac cancers for neuroendocrine and particularly ECL cell
diﬀerentiation.
2.MaterialandMethods
Thirty-two gastric carcinomas located to the cardia or
less than 1.5cm from oesophagus border were included
consecutively from the ﬁles of the Department of Pathology2 Gastroenterology Research and Practice
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Figure 1: 1 Immunohistochemical labelling of tumour cells in the gastric cardiac region in patient 4. Tumour cells label positive for CgA
(40x) (a), synaptophysin (b), and serotonin (c) 20x. Inserts 40x.
and Medical Genetics, St. Olavs Hospital. Twenty-six cases
were males (mean age 65.5 years) and six females (mean age
69.2 years). Table 1 shows the characteristics of the tumours.
The patient ﬁles were examined for use of proton pump
inhibitors (PPI), and we found long-term use (ten years or
more) in three patients.
Serial sections 4µm thick were cut from formalin-ﬁxed
paraﬃn-embedded tissue and deparaﬃnised. Sections for
morphology were stained for hematoxylin and eosin. Sec-
tions for immunohistochemical labelling were immersed in
3%hydrogenperoxide toblock endogenous peroxidase activ-
ity. Antigen retrieval before immunolabelling was achieved
by boiling the sections in Tris/EDTA-buﬀer pH 9.0 (synap-
tophysin, histidin decarboxylase (HDC), and serotonin)
or citrate-buﬀer pH 6.0 (Chromogranin A (CgA)) for 15
minutes. The sections were incubated with antibody against
synaptophysin (Code A010, Dakocytomation, Glostrup,
Denmark,1:200)andHDC(CodeB260-1,Eurodiagnostica,
1:15000) for 1 hour at room temperature, and CgA (Code
MO869, Dakocytomation, 1:2000) and serotonin (Code
6336, Abcam, 1:100) for 18 hours at 4◦C. Tyramide signal
ampliﬁcationwasusedtoincreasesensitivityofCgAlabelling
as described previously [19].
Antigen-antibody complexes were visualized using the
Envision-HRP kit (K5007, Dakocytomation) and AEC
(SK4200, Vector laboratories Burlingame, CA) or DAB+
(K5007, Dakocytomation). Finally, the sections were coun-
terstained with haematoxylin.
Diﬀerences between groups were evaluated using
two-tailed Mann-Whitney U test when comparing.
P values < 0.05 were considered statistically signiﬁcant. Sta-
tistical analyses were done using Graphpad Prism 4.0
(Graphpad Software Inc., San Diego, CA).
The study was approved by The Regional Committee for
Medical Research Ethics in Trondheim, Norway.
3. Results
According to Laurens classiﬁcation, 23 of the 32 tumours
were classiﬁed as intestinal type, ﬁve as diﬀuse type, three of
mixed type, and one undetermined (Table 1).
There was a male predominance: 26 male and 6 female
patients.
In 15 of the 32 tumours, some tumour cells were positive
foroneormoreneuroendocrinemarkers,CgAandserotonin
in ﬁve cases. Three of these were also positive for HDC
(Figure 1). Seven were positive for one marker only, synap-
tophysin most predominantly (Table 2). One patient had
linear hyperplasia and micronodules positive for HDC andGastroenterology Research and Practice 3
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Figure 2: Immunohistochemical labelling of tumour cells in the gastric cardiac region in patient 9 demonstrating positive labelling of CgA
(a and c) and HDC (b and d) (20x). Inserts 40x.
CgA in mucosa adjacent to the tumour (Figure 2). HDC-and
serotonin-positive cells were present in the normal gastric
mucosa. There was a nonsigniﬁcant tendency that female
patients more often had neuroendocrine diﬀerentiation (5 of
6w o m e nv e r s u s9o f2 6m e n ,P = 0.07).
There was no diﬀerence in frequency of neuroendocrine
diﬀerentiation between diﬀuse and intestinal cancers (4 of 8
diﬀuse versus 10 of 24 intestinal, P = 0.74).
There was no diﬀerence in age between patients with
neuroendocrine labelling or without neuroendocrine stain-
ing (67 ± 3 years versus 68 ± 2 years). Three patients
reported use of PPI, and two of these had neuroendocrine
labelling of tumour cells. In the normal-appearing mucosa
outside the carcinomas, there were cells positive for HDC
in most patients, indicating that ECL cells are present in the
normal cardia.
4. Discussion
Gastric carcinomas in the cardiac region have shown an
unexplained increase in frequency [2–6], and it was of
interest to see if this increase could be related to use of
PPI. Carcinomas developing in hypergastrinemic patients
are immunoreactive for neuroendocrine markers, and we
therefore examined cardia cancers for such markers.
In rats, gastric cancers develop from the ECL-cells after
long-term treatment with omeprazole, a potent PPI [22].
Nevertheless, omeprazole and later other PPIs were accepted
for clinical use based upon the assumption that ECL-cell-
derived gastric tumours were rare or insigniﬁcant in man.
On the other hand, although PPI treatment results in ECL
cell hyperplasia [23], only one indirect report on ECL cell
carcinoids during treatment with PPI exists [24]. Moreover,
after extensive use of PPIs in Western countries for at
least ﬁfteen years, there has been no report conﬁrming an
association between the increase in gastric carcinomas and
PPI use. However, there is an absolute increase in gastric
carcinomas of diﬀuse type, particularly of signet-ring cell
subtype [25] among which ECL-cell-derived carcinomas
were most often found [18, 21, 26, 27]. There is also an
increase in noncardia gastric carcinomas in the younger age-
groups in the USA [28].
An epidemiological study found an association between
use of PPI and oesophageal carcinomas and noncardia car-
cinomas, but not with cardiac carcinomas [29]. The major
limitationofthatstudywastheshortmedicationtime(mean
3 years), and the ﬁndings could be a result of the foregoing
disease and not the medication. Our study is a relatively
small study but larger prospective studies of patients using
long-term PPI have so far not been published. We found4 Gastroenterology Research and Practice
Table 1: Characteristics of gastric cardiac carcinomas.
Case
no.
Tumour
diameter
(cm)
Histological
grading
Lauren
classiﬁcation
Depht of
inﬁltration
Lymph
nodes
with
metastasis
13 M d I n t S s 6 / 7
2 4 Muc Int Mp 3/12
38 P d D i ﬀ Ss 1/9
43 , 2 P d M i x S s 0 / 1 2
5 3 Pd Int Mp 10/12
66 P d M i x S s 2 / 1 2
74 P d I n t S s 6 / 1 8
84 , 5 M d I n t S s 5 / 8
9 4 Pd Int Ss 10/10
10 1,2 Md Int Ss 0/6
11 3,2 Hd Int Mp 6/11
12 4 Muc Mix Ss 3/5
13 4,5 Pd Int Ss 2/12
14 9 Pd Int Ss 8/12
15 4,5 Md Int Ss 2/11
16 5 Pd Int Ss 3/5
17 5 Md Int Ss 0/2
18 6 Md Int Ss 12/16
19 3,0 Pd Diﬀ Ss 3/9
20 4,6 Pd Int Ss 7/11
21 4,2 Md Int Mp 0/11
22 2,2 Md Int Ss 2/2
23 5,0 Pd Diﬀ Ss 2/16
24 4,0 Pd Int Ss 0/1
25 2,5 Pd Diﬀ Ss 1/9
26 4,0 Ld Int Ss 12/14
27 5,0 Ld Undetermined Ss 3/15
28 4,8 Md Int Ss 2/3
29 2,0 Pd Diﬀ Ss 5/7
30 9,0 Md Int Ss 1/6
31 5,7 Md Int Ss 0/3
32 4,0 Ld Int Ss 2/13
Pd: Poorly diﬀerentiated, Md: Moderately diﬀerentiated, Hd: Highly
diﬀerentiated, Muc: Mucinous, Int: Intestinal, Diﬀ:D i ﬀuse, Mix: Mixed
type, Mp: The tumour grows into but not through muscularis propria, Ss:
The tumour grows through muscularis propria.
that only three of thirty-two patients with gastric cardiac
carcinoma had been using PPI for more than 10 years. A
signiﬁcant association between PPI and cardiac carcinoma
could not be detected in this study, and this study does not
supportthehypothesisthatuseofinhibitorsofacidsecretion
could explain the increased occurrence of gastric carcinomas
localized to the cardia.
Human gastric carcinomas are divided into two types
according to Lauren: diﬀuse and intestinal [30], with dif-
ferent epidemiology, risk factors, and cell of origin [18].
Twenty-three of the thirty-two patients had an intestinal
Table 2: Neuroendocrine diﬀerentiation in gastric carcinomas
localizedtothecardiaandlong-termuseofprotonpumpinhibitors.
Case
no. CgA Synaptophysin HDC Serotonin Use of
PPI
1 −− − − −
2 −− − − −
3 −− − − −
4+ + − + −
5+ −− ++
6 −− − − −
7 −− − − −
8 −− − − −
9+ − ++ −
10 −− − − −
11 + + + + +
12 −− − − −
13 −− − − +
14 −− − − −
15 −− − − −
16 −− − − −
17 −− − − −
18 + −− −−
19 + −− −−
20 + + −− −
21 − + −− −
22 − + −− −
23 − + −− −
24 + + −− −
25 − + −− −
26 −− − − −
27 −− − − −
28 + −− −−
29 + + −− −
30 −− − − −
31 + + + + −
32 −− − − −
type, and ﬁve had a diﬀuse type. Three were classiﬁed as
a mixed type. Other studies have also reported that cardia
cancersarepredominantlyofintestinaltype[14,31],whereas
ECL-cell-derived cancer developing in hypergastrinemic
patientswithperniciousanaemiaareofthediﬀusetype[19].
Inthepresentstudy,ﬁfteenofthirty-threecasesofgastric
cardiac cancer expressed neuroendocrine markers, ten of
these were classiﬁed as intestinal type, ﬁve were diﬀuse, and
one had a mixed growth pattern. This does not lend support
to the hypothesis that ECL-cell-derived tumours develop in
gastric cardia.
Three patients reported use of PPI, and two of these had
neuroendocrine staining of the tumour cells. These tumours
were serotonin immunoreactive. The mechanisms involved
in growth regulation of EC cells are not known, but there areGastroenterology Research and Practice 5
no studies supporting that gastrin acts as a growth factor for
EC cells.
However, the serotonin-positive tumours also stained
weakly positive for HDC, an ECL cell marker. One possible
explanation is that EC cells and ECL cells are closely related,
and during malignant transformation, the EC cells could
e x p r e s sE C Lc e l lm a r k e r sa n dv i c ev e r s a .
The existence of a normal cardiac mucosa has been ques-
tioned, and the physiological role of this tissue is unknown.
T h em u c o s ac o n s i d e r e dt ob en o r m a li nc a r d i ac o u l db ea
metaplastic area that develops as a result of gastroesophageal
reﬂux disease [32, 33], a view that has been contradicted
by others [34]. Distal extension of cardia could arise from
atrophic gastritis, most commonly induced by H. pylori
infection.
The neuroendocrine cells in cardia are not well char-
acterized. The extracardiac gastric mucosa contains various
neuroendocrine cells such as ECL cells, G cells, A-like cells,
and D cells, while the cardia is believed to contain only
serotonin-producing cells, i.e., EC cells [16]. However, ECL
cells, which are the most abundant neuroendocrine cell in
the oxyntic mucosa, were not examined for in this study.
We have found that ECL cells are present in the gastric
cardiac mucosa outside the tumours, indicating that the
cardiac region resembles the oxyntic mucosa as regards the
neuroendocrine cell population.
In conclusion, almost half the cardia cancers expressed
neuroendocrine markers, but few patients had been long-
term PPI users. The present study does not provide evidence
that use of inhibitors of acid secretion could explain the
increased occurrence of gastric carcinomas localized to the
cardia.
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